RedHill Biopharma Advances Opaganib For Ebola Treatment With BARDA Funding, Aiming To Tackle Global Health Preparedness
Portfolio Pulse from Benzinga Newsdesk
RedHill Biopharma's opaganib has been selected by BARDA for joint development and funding as a medical countermeasure for Ebola virus disease. This collaboration aims to advance opaganib towards potential FDA approval, following positive results in U.S. Army-funded studies. The drug shows promise as a mutation-resistant antiviral and anti-inflammatory treatment, addressing the urgent need for effective Ebola therapies.
October 14, 2024 | 11:13 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
RedHill Biopharma's opaganib has been chosen by BARDA for development as an Ebola treatment, with funding to advance towards FDA approval. This could enhance RedHill's position in the biotech sector.
The selection of opaganib by BARDA for joint development and funding is a significant endorsement, likely to positively impact RedHill Biopharma's stock. The potential FDA approval as a medical countermeasure for Ebola could enhance the company's market position and investor confidence.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100